Company intelligence / Profile preview
R-Pharm
- Ownership
- Private
- Employees
- ~3350
- Development stage
- Phase 3
Overview
R‑Pharm has a broad commercial portfolio with products spanning oncology, autoimmune diseases, antivirals—including an approved COVID‑19 drug ("Coronavir")—and other specialty therapeutics. The company also develops APIs and biotechnological substances. It collaborates with global pharma companies for manufacturing/localization and has recently expanded into medical devices such as microfluidic chips for reproductive medicine. Clinical research partnerships include major Russian academic institutions.
- Therapeutic areas
- CardiovascularImmunologyHematologyOtherOncologyInfectious Diseases
- Modalities
- Small moleculesBiologics/biotechnological substancesActive pharmaceutical ingredients (APIs)Medical devices/microfluidic chipsAntibodies and immunotherapies (inferred from oncology/immunology focus)
- Industry
- Biotech
Drug pipeline
13 assets12 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on R-Pharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R-Pharm.